(Image source: Photo.com)
Astragalus, as a treasure of Chinese herbal medicine, has been widely valued by the medical community since ancient times. The "Compendium of Materia Medica" is praised as the top grade in medicinal materials, with extremely high medicinal value. However, in recent years, one of the major challenges faced by Astragalus cultivation is root rot, which is caused by the combined infection of multiple pathogenic bacteria, which has a serious impact on the yield and quality of Astragalus.
In order to overcome this problem, the team of Professor Gao Wenyuan of the School of Pharmacy of Tianjin University has developed a new biological bacteriostatic agent, which provides a new environmentally friendly and efficient solution for the prevention and control of Astragalus root rot.
According to the latest reports, the new biological bacteriostatic agent successfully developed by Professor Gao Wenyuan's team can not only inhibit root rot, which is known as "plant cancer", but also promote the growth and metabolism of Astragalus membranaceus, making Astragalus plants healthier and stronger. Recently, the results have been published in the internationally renowned journal Journal of Chemical Engineering.
Professor Gao Wenyuan's team deeply discussed the antibacterial mechanism of the bacteriostatic agent. Experiments have found that the bacteriostatic agent can inhibit the growth genes of pathogenic bacteria such as Fusarium oxysporum, thereby blocking its reproduction process. At the same time, it can also stimulate the production of antibacterial components in Astragalus and enhance the disease resistance of Astragalus itself. In addition, the bacteriostatic agent can also activate the resistance gene of Astragalus, so that Astragalus can respond quickly in the face of pathogenic bacterial invasion and reduce the damage of the disease to the plant.
Wang Juan, a key member of the team and an associate professor at the School of Pharmacy at Tianjin University, said: "The new bacteriostatic agent we have developed is as effective as the pesticides currently on the market, but at a lower cost and more environmentally friendly. This means that farmers can not only reduce the economic burden when using this bacteriostatic agent, but also reduce environmental pollution and achieve green planting. ”
A bacteriostatic is a chemical or biological agent that can inhibit the growth and reproduction of bacteria, fungi, or other microorganisms. In agriculture and medicine, bacteriostatic agents are often used to prevent the spread of disease or to control damage caused by microorganisms. In agriculture, bacteriostatic agents can be used to control plant diseases, while in the field of medicine, bacteriostatic agents can be used to treat or prevent bacterial or fungal infections.
Biologics account for more than 70% of the global immunosuppressant market share
According to data from Frost &Sullivan, biologics accounted for more than 70% of the global immunosuppressant market in 2022, and these biologics are various biologics. Thus, it can be seen that in the global market, biologics have become a major product in the immunosuppressant industry.
China's pharmaceutical R&D spending is growing faster than the global level
The R&D of biologics is a huge undertaking that typically includes four phases: drug discovery, preclinical research, clinical trials, and post-marketing studies. The pre-IND phase includes drug discovery and preclinical studies. According to relevant data, it takes an average of at least 10 years for an ordinary biopharmaceutical company to develop an innovative drug, while it takes an average of 6 to 7 years for the clinical trial stage. Therefore, accelerating the development process is essential to facilitate global biomedical innovation.
With government policies and the support of pharmaceutical companies, China has actively promoted pharmaceutical research and development. China's pharmaceutical R&D expenditure increased from RMB78.8 billion in 2016 to RMB170.3 billion in 2020, with a compound annual growth rate of 21.3%.
Global Biologics Market Size Forecast
According to forecasts, global biologics will rise to $530.1 billion in 2025 at a CAGR of 12.2% from 2021 to 2025. It then rose to $804.9 billion in 2030 at a CAGR of 8.7%.
The biologics industry is an area full of potential and growth opportunities. With the improvement of people's awareness of health and environmental protection, biologics, as a natural and environmentally friendly biotechnology product, have received more and more attention and favor. Biological agents can be used in agriculture, medicine, environmental protection and other fields, and have broad market prospects. With the continuous progress and innovation of science and technology, the R&D and application of biologics will continue to expand, bringing more development opportunities and market space to the industry. It is foreseeable that the biologics industry will become a hot area for future development and make greater contributions to social health and environmental protection.
Prospective Economist APP Information Group
For more research and analysis of this industry, please refer to the "Analysis Report on the Development Prospect Forecast and Investment Strategic Planning of China's Biopharmaceutical Industry" by Qianzhan Industry Research Institute
At the same time, the Prospective Industry Research Institute also provides solutions such as industrial big data, industrial research reports, industrial planning, park planning, industrial investment, industrial mapping, smart investment promotion system, industry status certificate, IPO consulting/fundraising and investment feasibility study, and specialized and special new small giant declaration. To quote the content of this article in any public information disclosure such as prospectus and annual report, formal authorization from Qianzhan Industry Research Institute is required.
More in-depth industry analysis is available in the [Prospective Economist APP], and you can also communicate and interact with 500+ economists/senior industry researchers. More enterprise data, enterprise information, and enterprise development are all in the [Qichamao APP], the most cost-effective and most comprehensive enterprise query platform.